Overview
We are moving Guardant from our Long Bias list to the Best Idea Long roster. Over the last several weeks, claims volume across our trackers for genetic testing companies (ping us for the chartbook) have been accelerating sequentially. The claims series have their limitations, but for Guardant and others, the trend has been a leading indicator of reported volume and revenue. Based on the current trend, Guardant appears likely to report a very strong clinical test volume number for 3Q20 of >18,000 tests. Based on our model, the upside to clinical test volume would produce revenue of ~76M versus consensus of $65.9. Management has yet to reinstate guidance since the beginning of the pandemic.
We will be reviewing the claims data on our weekly Position Monitor update call today at 12:30pm ET.
|
Health Care Webcast | The Big Three, AMN Recovery, Genetic Testing Please join us on Monday, October 19, 2020 @ 12:30 PM ET - Add to Outlook Calendar FREE: CLICK HERE for event details (including video and materials links). |
All data available upon request. Please reach out to with any inquiries.
Thomas Tobin
Managing Director
Twitter
LinkedIn
